



9.15-04

JFV

RECEIPT NO.: ISIS-5325

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Charles Allerson, et al.

Confirmation No.: 5641

Application No.: 10/701,007

Group Art Unit: 1645

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

For: **COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATIONS**EXPRESS MAIL LABEL NO: EL998519145US
DATE OF DEPOSIT: September 14, 2004

EL998519145US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - Certification in Accordance with § 1.97(e) is attached; or
 - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers 104 - 111 listed on the attached Form PTO-1449 are enclosed herewith.
- A copy of reference number 112 on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
- Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.
- The relevance of those listed references which are not in the English language is as follows:

Enclosed is a copy of the PCT International Search Report dated August 23, 2004 (number 104 on Form PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 14, 2004

John A. Harrelson, Jr.
John A. Harrelson, Jr.
Registration No. 42,637

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISIS-5325	Application No. 10/701,007
		Applicant Charles Allerson, et al.	
		Filing Date November 4, 2003	Group 1645
		Confirmation No. 5641	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
104	Copy of the PCT International Search Report dated August 23, 2004 (PCT/US03/35063)		
105	Beigelman, L., et al., "Chemical modification of hammerhead ribozymes," <i>J. of Biological Chem.</i> , 1995 , 270(43), 257082-25708		
106	Caplen, N.J., et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," <i>PNAS</i> , 2001 , 98(17), 9742-9747		
107	Czauderna, F., et al., "Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells," <i>Nucleic Acids Res.</i> , 2003 , 31(11), 2705-2716		
108	Elbashir S.M., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , 2001 , 411, 494-498		
109	Paddison, P.J., et al., "Stable suppression of gene expression by RNAi in mammalian cells," <i>PNAS</i> , 2002 , 99(3), 1443-1448		
110	Sui, G., et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , 2002 , 99(8), 5515-5520		
111	Yu, J.-Y., et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , 2002 , 99(9), 6047-6052		
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified	Docket No. ISIS-5325	Application No. 10/701,007
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Charles Allerson, et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date November 4, 2003	Group 1645
	Confirmation No. 5641	

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

EXAMINER

DATE CONSIDERED